GS

EQS-News: SGL Carbon achieves annual targets for 2023 and invests more in growth markets

Retrieved on: 
Wednesday, April 10, 2024
Carbon, Carbon fibers, Uncertainty, Face, Growth, Environment, CFO, Pension, Standstill, SGL, Sale, Graphite, CS, SGL Carbon, Wind, Silicon, ROCE, Investment, Annual report, Depreciation, GS, LED, Corporation

The contribution of the individual business units to SGL Carbon's adjusted EBITDA reflects the sales development already described.

Key Points: 
  • The contribution of the individual business units to SGL Carbon's adjusted EBITDA reflects the sales development already described.
  • The projected operating loss of CF will have a negative impact on the adjusted EBITDA of the SGL Carbon Group in 2024.
  • We will continue to expand production capacities in this sector to secure future profitable growth for SGL Carbon.
  • Further details on business development in 2023 and the outlook for 2024 can be found in SGL Carbon's Annual Report.

Gouverneur Bancorp, Inc. Announces Appointment of New President and Chief Executive Officer

Retrieved on: 
Wednesday, March 27, 2024
First Niagara Bank, Bank, Commercial, GS, OTCQB, Credit union

GOUVERNEUR, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Gouverneur Bancorp, Inc. (OTCQB Marketplace: GOVB) (the “Company”), the holding company for Gouverneur Savings and Loan Association (the “Bank”), announced today that the Board of Directors of the Company and the Bank has appointed Robert W. Barlow as the President and Chief Executive Officer of the Company and the Bank effective immediately.

Key Points: 
  • GOUVERNEUR, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Gouverneur Bancorp, Inc. (OTCQB Marketplace: GOVB) (the “Company”), the holding company for Gouverneur Savings and Loan Association (the “Bank”), announced today that the Board of Directors of the Company and the Bank has appointed Robert W. Barlow as the President and Chief Executive Officer of the Company and the Bank effective immediately.
  • Charles C. Van Vleet, Jr. will continue to serve as the President and Chief Executive Officer of GS&L Municipal Bank, the wholly owned subsidiary of the Bank, and will assist with Mr. Barlow’s transition to the role of President and Chief Executive Officer.
  • Mr. Barlow has served as Vice President of Commercial and Residential Lending for Northern Credit Union, located in Watertown, New York, since September 2019.
  • Mr. Barlow also served as Vice President and Branch Manager for First Niagara Bank, N.A.

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Plantar fibromatosis, Radiation, Gene, Growth, Sarcoma, Blood, Disease, Patient, Committee, Knowledge, Tissue, Regulation, Cancer, EMA, IRIS, Radiation therapy, European, Therapy, COMP, Aggressive fibromatosis, Safety, European Commission, GS, Pain, Marketing, Swelling, Medicine, Pharmaceutical industry

Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Key Points: 


Orphan designation: Nirogacestat Treatment of soft tissue sarcoma, 17/10/2019 Positive

Infortrend Fuels HPC Workloads in a Government-Affiliated Laboratory in India

Retrieved on: 
Tuesday, March 12, 2024
Research, Forecasting, Computing, RDMA, SSD, NVM Express, HPC, Meteorology, Infortrend, Weather, WRF, Data management, IOPS, GS, TB, Model, Computer data storage

The Indian government-affiliated research laboratory is the country's prime center specializing in fundamental and applied research in atmospheric and space sciences.

Key Points: 
  • The Indian government-affiliated research laboratory is the country's prime center specializing in fundamental and applied research in atmospheric and space sciences.
  • For weather forecasting and atmospheric research needs, the laboratory leverages the WRF Model running on the on-premises HPC cluster.
  • Recently, the HPC cluster has expanded, and so has the complexity of the WRF Model.
  • We chose Infortrend because it offers high-performance and high-capacity storage at a competitive price," said the head of the Computing and Data Management Division at the Research Laboratory.

Infortrend Fuels HPC Workloads in a Government-Affiliated Laboratory in India

Retrieved on: 
Tuesday, March 12, 2024
Research, Forecasting, Computing, RDMA, SSD, NVM Express, HPC, Meteorology, Infortrend, Weather, WRF, Data management, IOPS, GS, TB, Model, Computer data storage

The Indian government-affiliated research laboratory is the country's prime center specializing in fundamental and applied research in atmospheric and space sciences.

Key Points: 
  • The Indian government-affiliated research laboratory is the country's prime center specializing in fundamental and applied research in atmospheric and space sciences.
  • For weather forecasting and atmospheric research needs, the laboratory leverages the WRF Model running on the on-premises HPC cluster.
  • Recently, the HPC cluster has expanded, and so has the complexity of the WRF Model.
  • We chose Infortrend because it offers high-performance and high-capacity storage at a competitive price," said the head of the Computing and Data Management Division at the Research Laboratory.

GS Construction Marks 50 Years of Excellence in Underground Infrastructure

Retrieved on: 
Monday, March 11, 2024
GS, Culture, Family, History, Growth, Environment, Water

ACHESON, AB, March 11, 2024 /PRNewswire-PRWeb/ -- A Tradition of Expertise and Teamwork

Key Points: 
  • Celebrating half a century of innovation in underground infrastructure construction and water & drainage services, GS Construction, a multi-generation family-run business, proudly commemorates its 50th anniversary.
  • Since its inception in 1974, GS Construction has been at the forefront of building critical infrastructure projects that support their community's growth and sustainability.
  • "As we celebrate 50 years of GS Construction, we honour the culture, standards, and traditions that were established by Glen and that we continue to uphold.
  • Today, GS Construction continues to thrive under the leadership of Terran Sandwith, who has inherited the commitment to excellence and innovation.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

KBRA Assigns Rating to Goldman Sachs BDC, Inc.'s $400 Million 6.375% Senior Unsecured Notes Due 2027

Retrieved on: 
Wednesday, March 6, 2024
Banking, Professional Services, Finance, BDC, BBB, Goldman Sachs, Credit Corp Group, Issuer, Investment, Risk management, ESG, Diversification, Risk, Business Development Company, GS, KBRA, Professional services, Research, RIC

KBRA assigns a rating of BBB to Goldman Sachs BDC, Inc.'s (“GSBD” or “the company”) $400 million 6.375% senior unsecured notes due March 11, 2027.

Key Points: 
  • KBRA assigns a rating of BBB to Goldman Sachs BDC, Inc.'s (“GSBD” or “the company”) $400 million 6.375% senior unsecured notes due March 11, 2027.
  • The rating is supported by Goldman Sachs BDC, Inc.'s ties to Goldman Sachs' ("GS") $2.5 trillion of Assets Under Supervision along with SEC exemptive relief to co-invest with GS affiliates.
  • The company is managed by Goldman Sachs Asset Management, L.P. ("GSAM"), an affiliate of Goldman Sachs & Co. LLC.
  • GSBD's affiliate BDC, Goldman Sachs Private Credit Corp., is rated by KBRA (Issuer and Senior Unsecured Debt Ratings: BBB/Stable Outlook).

KBRA Expects to Rate Goldman Sachs BDC, Inc.'s Senior Unsecured Notes BBB

Retrieved on: 
Wednesday, March 6, 2024
Banking, Professional Services, Finance, BDC, BBB, Goldman Sachs, Credit Corp Group, Issuer, Investment, Risk management, Diversification, Risk, Business Development Company, GS, KBRA, Professional services, Research, RIC

KBRA expects to rate Goldman Sachs BDC, Inc.'s (“GSBD” or “the company”) issuance of senior unsecured notes BBB.

Key Points: 
  • KBRA expects to rate Goldman Sachs BDC, Inc.'s (“GSBD” or “the company”) issuance of senior unsecured notes BBB.
  • The rating is supported by Goldman Sachs BDC, Inc.'s ties to Goldman Sachs' ("GS") $2.5 trillion of Assets Under Supervision along with SEC exemptive relief to co-invest with GS affiliates.
  • The company is managed by Goldman Sachs Asset Management, L.P. ("GSAM"), an affiliate of Goldman Sachs & Co. LLC.
  • GSBD's affiliate BDC, Goldman Sachs Private Credit Corp., is rated by KBRA (Issuer and Senior Unsecured Debt Ratings: BBB/Stable Outlook).

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Monday, February 19, 2024
CE, Hospital, Com, Glucose meter, CGM, International Fair, MDR, Treatment, Booth, GS1, Conference, Emerging technologies, ATTD, GS, Prediabetes, Certification, GS2, Q&A, DSM-IV codes

LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024. The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference. According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes. SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.

Key Points: 
  • LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on 6-9 March 2024.
  • The company will showcase its latest CGM solutions for diabetes management at Booth No.15 at the conference.
  • According to SIBIONICS, it has collaborated with over 1,800 hospitals on integrating their CGM for inpatient treatment, benefiting over 850,000 individuals worldwide in managing diabetes.
  • SIBIONICS is constructing an automated production line with an annual capacity of 18 million CGM sets, expected to be completed within 2024.